Isoprostane as a promising biomarker in pulmonary arterial hypertension: Preanalytical and analytical viewpoints. Response to letter to the editor

被引：1
|
作者：
Zhang, Rui [1 ]
Jing, Zhi-Cheng [2 ,3 ]
机构：
[1] Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Cardiopulm Circulat, Shanghai 200092, Peoples R China
[2] Peking Union Med Coll, Thrombosis & Vasc Med Ctr, State Key Lab Cardiovasc Dis, Fu Wai Hosp, Beijing 100021, Peoples R China
[3] Chinese Acad Med Sci, Beijing 100730, Peoples R China
来源：
INTERNATIONAL JOURNAL OF CARDIOLOGY | 2014年 / 177卷 / 02期
关键词：
15-F2t-IsoP; Idiopathic pulmonary arterial hypertension; Prognosis; Biomarkers; Preanalytical and analytical; MASS-SPECTROMETRY; PLASMA SAMPLES; F-2-ISOPROSTANES; QUANTIFICATION; 15-F-2T-ISOPROSTANE; STRESS; URINE;
D O I：
10.1016/j.ijcard.2014.09.122
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：632 / 633
页数：2
相关论文
共 38 条
  • [1] Isoprostane as a promising prognostic biomarker in pulmonary arterial hypertension: preanalytical and analytical viewpoints
    Monneret, Denis
    Cracowski, Jean-Luc
    Bonnefont-Rousselot, Dominique
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2014, 177 (02) : 527 - 528
  • [2] CTLA-4 Expression Is a Promising Biomarker of Idiopathic Pulmonary Arterial Hypertension and Allows Differentiation of the Type of Pulmonary Hypertension
    Tomaszewski, Michal
    Malkowska, Paulina
    Sierawska, Olga
    Hrynkiewicz, Rafal
    Mroczek, Ewa
    Darocha, Szymon
    Hymos, Anna
    Blaszczak, Piotr
    Grywalska, Ewelina
    Niedzwiedzka-Rystwej, Paulina
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (24)
  • [3] From heart to blood: LTBP-2 is a promising biomarker for pulmonary arterial hypertension
    Nature Cardiovascular Research, 2022, 1 : 804 - 805
  • [4] From heart to blood: LTBP-2 is a promising biomarker for pulmonary arterial hypertension
    Potus, Francois
    Boucherat, Olivier
    NATURE CARDIOVASCULAR RESEARCH, 2022, 1 (09): : 804 - 805
  • [5] Response to letter to the editor "noninvasive determinants of pulmonary hypertension in interstitial lung disease"
    Joseph, Phillip
    Savarimuthu, Stella
    Oakland, Hannah T. T.
    Cullinan, Marjorie
    Heerdt, Paul M. M.
    Singh, Inderjit
    PULMONARY CIRCULATION, 2023, 13 (02)
  • [6] Heart Rate Variability as a Novel Biomarker of Treatment Response in Pulmonary Arterial Hypertension
    Jose, A.
    McCormack, F. X.
    Elwing, J. M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [7] Response to Letter to the Editor Analysis of Novel Cardiovascular Biomarkers in Patients With Pulmonary Hypertension (PH)
    Mirna, Moritz
    Lichtenauer, Michael
    HEART LUNG AND CIRCULATION, 2019, 28 (11): : E149 - E150
  • [8] Response to Letter Regarding Article, "Advances in Therapeutic Interventions for Patients With Pulmonary Arterial Hypertension"
    Lau, Edmund M. T.
    Montani, David
    Jais, Xavier
    Sitbon, Olivier
    Simonneau, Gerald
    Humbert, Marc
    CIRCULATION, 2015, 132 (12) : E154 - E154
  • [9] Response to Letter to Editor re: “Screening for pulmonary hypertension in preterm infants—not ready for prime time”
    Gautham Suresh
    Brian King
    Sunil K. Jain
    Journal of Perinatology, 2018, 38 : 1711 - 1713
  • [10] Response to the letter to the editor: Right ventricular dyssynchrony predicts clinical outcomes in patients with pulmonary hypertension
    Murata, Mitsushige
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2017, 234 : 129 - 130
1234